about
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disordersIncreasing antipsychotic dose for non response in schizophreniaIncreasing antipsychotic dose versus switching antipsychotic for non response in schizophreniaPerphenazine for schizophreniaSwitching antipsychotic for non response in schizophreniaPerphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaFlupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaFluphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaHaloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaBenzodiazepines for schizophreniaMaintenance treatment with antipsychotic drugs for schizophreniaHaloperidol versus first generation antipsychotics for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaPerazine for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaAmitriptyline versus placebo for major depressive disorderAntidepressants for central painZotepine versus other atypical antipsychotics for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaAmitriptyline versus placebo for major depressive disorderFlupenthixol versus low-potency first generation antipsychotic drugs for schizophreniaFluphenazine versus low-potency first generation antipsychotic drugs for schizophreniaHaloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaAcamprosate for alcohol dependenceSecond-generation antipsychotics for major depressive disorder and dysthymiaSecond-generation antipsychotics for anxiety disordersSecond-generation antipsychotics for obsessive compulsive disorderOpioid antagonists for alcohol dependenceClozapine versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaPerphenazine versus low-potency first generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first generation antipsychotic drugs for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaZotepine versus other atypical antipsychotics for schizophreniaSecond-generation antipsychotic drugs for anxiety disordersQuetiapine versus other atypical antipsychotics for schizophrenia
P50
Q24186601-2B25FDDF-02E5-4F9B-975A-3D169F391758Q24186768-37E8BDA4-25CE-4244-9B1B-7818FC139F9FQ24186772-E843DA00-E533-41BE-ABBD-B36ABCD6BAC5Q24187359-FB7EE83B-93BB-46DE-BE66-C41F48EB0786Q24187478-AD90EDE8-B6A4-4E92-AD82-78C7089245CEQ24193168-2872DE72-4DA1-4641-8229-E7C1929FBDE1Q24193881-A5775706-3916-4596-9421-AC7FC8CEAEDDQ24194501-E108ED4C-7E2B-48F3-BC03-62C165EAFA84Q24194891-458BE3DC-40F9-4B30-912A-F9291115A5D9Q24194898-9E4B2529-2D0E-4237-AA70-FB101D39A3A3Q24197501-635F44EB-109F-4A65-86EE-157082376B69Q24197902-E5B8894A-D2AA-414E-A822-07EEB6408568Q24198264-270E979C-3F4B-4CE1-8EAC-4C9E80A9AF2CQ24200904-77432795-1289-40EF-A874-1A42638B92A9Q24201125-4AD8E673-44D2-4D26-9D6A-99335AA44A00Q24201232-7623FF0D-B086-484F-BD9B-FB9AACD572D5Q24202427-48EEE4AF-85D0-44E5-957A-7E5AB5F8D949Q24202486-89399E15-B959-4580-B0AC-6BD4D0FDEDCBQ24234076-CA78C852-19BE-4056-8D23-ADCAB8054826Q24234683-10CCC54B-13F8-4167-905E-A7A9D4665741Q24234950-6881DAB7-FD17-450A-B567-9F8084584BC9Q24235000-76A6C46B-ED2F-4022-A683-4FC4F2523719Q24235116-8667CDF7-453B-4A4C-9D38-3EB3C61A7277Q24235274-3023254B-210C-45ED-9246-16043C300451Q24235300-E54C39F9-8D4F-4678-94F2-DD3AFDB5C100Q24235594-CCA34073-9112-41FA-B084-F30F1475ABCBQ24235667-951AE063-0150-4922-96D8-32D85CD5D752Q24235758-82F2BE64-210F-4414-8DCF-540DE99C6191Q24235770-9DA45579-2512-4C8A-A0AD-93102FEFF21FQ24235797-40DB31CF-6652-40B6-8C22-85DDF9B484CCQ24236422-F78DE99D-9F1B-4D22-8FBA-56ED0C24CFF7Q24236545-6E82E0E2-5402-4C21-8DB5-BDC582F0A004Q24236586-6162F76D-EA45-4158-B5F3-24C0DD170888Q24236681-BC9E0BB4-E803-4E95-963F-F2C72B5B08F9Q24240020-A5038818-9969-4FE8-8AE1-D855F0208AC1Q24240260-12C20E05-71DD-4EB1-A663-B93DC48A9722Q24240433-2570A1D0-7F3D-4270-96D2-23234E59F446Q24240500-D3F5F660-5C1E-40B6-BB56-558A0B80980EQ24240919-F5148F3D-251B-4DA6-B676-8D520A1D7113Q24240989-4FA07049-45CB-45C2-8734-35633DD2D814
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefan Leucht
@ast
Stefan Leucht
@en
Stefan Leucht
@es
Stefan Leucht
@sl
type
label
Stefan Leucht
@ast
Stefan Leucht
@en
Stefan Leucht
@es
Stefan Leucht
@sl
prefLabel
Stefan Leucht
@ast
Stefan Leucht
@en
Stefan Leucht
@es
Stefan Leucht
@sl